Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel

被引：367

作者：

Hirsch, Martin S. ^{[1
]}

Guenthard, Huldrych F. ^{[9
]}

Schapiro, Jonathan M. ^{[10
]}

Brun-Vezinet, Francoise ^{[11
]}

Clotet, Bonaventura ^{[12
]}

Hammer, Scott M. ^{[2
]}

Johnson, Victoria A. ^{[3
,4
]}

Kuritzkes, Daniel R. ^{[1
]}

Mellors, John W. ^{[5
]}

Pillay, Deenan ^{[13
]}

Yeni, Patrick G.

Jacobsen, Donna M. ^{[6
]}

Richman, Douglas D. ^{[7
,8
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA USA

[2] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[3] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA

[4] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA

[6] Int AIDS Soc USA, San Francisco, CA USA

[7] Univ Calif San Diego, San Diego, CA 92103 USA

[8] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA

[9] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

[10] Chaim Sheba Med Ctr, Tel Aviv, Israel

[11] Hop Bichat Claude Bernard, F-75877 Paris 18, France

[12] Hosp Badalona Germans Trias & Pujol, Irsi Caixa Fdn, Barcelona, Catalonia, Spain

[13] UCL Royal Free & Univ Coll Med Sch, London WC1E 6BT, England

来源：

CLINICAL INFECTIOUS DISEASES | 2008年 / 47卷 / 02期

关键词：

D O I：

10.1086/589297

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Resistance to antiretroviral drugs remains an important limitation to successful human immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment outcomes for infected individuals. The availability of new drugs from various classes, standardization of resistance assays, and the development of viral tropism tests necessitate new guidelines for resistance testing. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in drug-resistant HIV-1, drug management, and patient care to review recently published data and presentations at scientific conferences and to provide updated recommendations. Whenever possible, resistance testing is recommended at the time of HIV infection diagnosis as part of the initial comprehensive patient assessment, as well as in all cases of virologic failure. Tropism testing is recommended whenever the use of chemokine receptor 5 antagonists is contemplated. As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important.

引用

页码：266 / 285

页数：20

共 226 条

[1] Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G [J].